Abbott Laboratories shares surged 12% after the healthcare company reported strong second-quarter sales, raised its full-year earnings outlook and reaffirmed revenue growth guidance. Progress across its medical devices and diagnostics pipeline further boosted investor confidence in future growth.
AI’s 3 musketeers hit the brakes: Why Chris Wood sees midcaps back in favour
India’s domestic economy is showing resilience despite geopolitical and energy risks, with stronger bank credit, corporate lending and earnings growth. Jefferies’ Chris Wood sees a